Axelyf
Chestnut Hill, US · Founded 2025 · Delaware corporation · 14 employees on LinkedIn · 1 known investors
Axelyf develops RNA medicines built on nanotechnology formulations and nucleic acid technologies, working across the drug development pathway from CMC and clinical pharmacology to computational sciences. The company focuses on RNA therapeutics platform development and associated therapeutic programs.
Founders & leadership
Axelyf was founded in 2025 by Orn Almarsson.
OA
Orn AlmarssoninFounder
Board
AB
JL
John LucasBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$4.8M disclosed across 1 round · 2025
▶$4.8MraisedAug 2025 · 37 investors · BiotechnologyRule 506(b)
▶$4.8MraisedAug 2025 · 37 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- John LucasDirector
- Arni BlondalDirector
- Orn AlmarssonExecutive Officer, Director, Promoter
- Offering amount
- $6.3M
- Amount sold
- $4.8M
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
In the news
Frequently asked questions
- What does Axelyf do?
- Axelyf develops RNA medicines built on nanotechnology formulations and nucleic acid technologies, working across the drug development pathway from CMC and clinical pharmacology to computational sciences. The company focuses on RNA therapeutics platform development and associated therapeutic programs.
- Who founded Axelyf?
- Axelyf was founded by Orn Almarsson in 2025.
- Who are Axelyf's investors?
- Axelyf's investors include Brunnur Ventures GP.
- How much funding has Axelyf raised?
- Axelyf has disclosed $4.8M raised across 1 round.
- Where is Axelyf headquartered?
- Axelyf is headquartered in Chestnut Hill, US.